DK3688032T3 - Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder - Google Patents

Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder

Info

Publication number
DK3688032T3
DK3688032T3 DK18822166.7T DK18822166T DK3688032T3 DK 3688032 T3 DK3688032 T3 DK 3688032T3 DK 18822166 T DK18822166 T DK 18822166T DK 3688032 T3 DK3688032 T3 DK 3688032T3
Authority
DK
Denmark
Prior art keywords
methods
receptor molecules
engulfment receptor
chimeric engulfment
chimeric
Prior art date
Application number
DK18822166.7T
Other languages
English (en)
Inventor
Daniel Mark Corey
Original Assignee
Cero Therapeutics Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cero Therapeutics Holdings Inc filed Critical Cero Therapeutics Holdings Inc
Application granted granted Critical
Publication of DK3688032T3 publication Critical patent/DK3688032T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18822166.7T 2017-09-26 2018-09-21 Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder DK3688032T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762563615P 2017-09-26 2017-09-26
US201862649529P 2018-03-28 2018-03-28
US201862652822P 2018-04-04 2018-04-04
PCT/US2018/052297 WO2019067328A1 (en) 2017-09-26 2018-09-21 CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
DK3688032T3 true DK3688032T3 (da) 2025-12-15

Family

ID=64744922

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18822166.7T DK3688032T3 (da) 2017-09-26 2018-09-21 Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder

Country Status (14)

Country Link
US (2) US11708423B2 (da)
EP (2) EP4714966A2 (da)
JP (3) JP7286658B2 (da)
KR (1) KR20200100598A (da)
CN (1) CN111386284B (da)
AU (1) AU2018341244A1 (da)
CA (1) CA3073421A1 (da)
DK (1) DK3688032T3 (da)
ES (1) ES3058444T3 (da)
FI (1) FI3688032T3 (da)
IL (1) IL272803A (da)
MX (1) MX2020007266A (da)
RU (1) RU2020114641A (da)
WO (1) WO2019067328A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
RU2019112860A (ru) 2016-09-27 2020-10-30 Серо Терапьютикс, Инк. Молекулы химерных интернализационных рецепторов
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
EP3774865A1 (en) * 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
US20210015865A1 (en) * 2018-03-28 2021-01-21 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
WO2019191334A1 (en) * 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
WO2021067875A1 (en) * 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
US20240122980A1 (en) * 2019-10-18 2024-04-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of tim-3 cytoplasmic tail in chimeric antigen receptors
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CA3173480A1 (en) * 2020-03-31 2021-10-07 Kathleen Boyle Modified b cells and methods of use thereof
WO2022036265A1 (en) * 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
US20240285682A1 (en) * 2020-08-14 2024-08-29 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022036287A1 (en) * 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
CA3189480A1 (en) * 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
CN112194726B (zh) * 2020-09-02 2023-06-23 沣潮医药科技（上海）有限公司 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
EP4247856A4 (en) * 2020-11-18 2024-10-30 Carina Biotech Pty Ltd CHIMERIC ANTIGEN RECEPTOR T CELL AND METHODS
EP4279596A4 (en) * 2021-01-15 2025-01-22 National University Corporation Tokai National Higher Education and Research System CHIMERIC TARGET FACTOR RECEPTOR
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
CA3256055A1 (en) * 2022-03-30 2023-10-05 Shoreline Biosciences, Inc. Chimeric antigen receptors for natural killer cells and their uses in immunotherapy
WO2024086791A2 (en) * 2022-10-21 2024-04-25 Shoreline Biosciences, Inc. Chimeric receptors and uses thereof

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1998A (en) 1841-03-12 Refrigerator
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (da) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5641875A (en) 1993-09-30 1997-06-24 University Of Pennsylvania DNA encoding chimeric IgG Fc receptor
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
JPH10234372A (ja) 1997-02-27 1998-09-08 Boehringer Mannheim Corp キメラ受容体を有する細胞とその作成方法、並びに その利用
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
WO2001066785A1 (en) 2000-03-08 2001-09-13 National Jewish Medical And Research Center Phosphatidyl serine receptors and uses thereof
WO2001068709A1 (en) 2000-03-14 2001-09-20 Idec Pharmaceuticals Corporation Antibodies that bind phosphatidyl serine and a method of their use
US20030072743A1 (en) * 2000-05-05 2003-04-17 Matthew Albert Genetic manipulation of phagocytes for modulation of antigen processing and the immune response therefrom
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US8709412B2 (en) * 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
JP4572276B2 (ja) 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
US20060002940A1 (en) 2002-03-15 2006-01-05 Jennifer Stevenson Method of immunotherapy
US7247303B2 (en) 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
WO2004067569A1 (en) 2003-01-27 2004-08-12 Crucell Holland B.V. Internalising human binding molecules against cd72
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005097211A2 (en) 2004-03-24 2005-10-20 Telos Pharmaceuticals, Inc. Compositions as adjuvants to improve immune responses to vaccines and methods of use
GB0414055D0 (en) 2004-06-23 2004-07-28 Univ Edinburgh Specific binding members and uses thereof
CN101146826A (zh) 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
PL2427212T3 (pl) 2009-05-08 2018-02-28 Vaccinex, Inc. Przeciwciała anty cd-100 i sposoby ich zastosowania
US20110165649A1 (en) 2010-01-06 2011-07-07 Brett Tyler Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013192294A1 (en) 2012-06-20 2013-12-27 Boston 3T Biotechnologies, Inc. Cellular therapies for treating and preventing cancers and other immune system disorders
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
EP3763810A3 (en) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US20140162290A1 (en) 2012-11-22 2014-06-12 Riken Probe for detecting dead cell
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
CA3190002A1 (en) * 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
DK3149031T3 (da) 2014-05-29 2020-03-16 Us Health Anti-human papillomavirus 16 e7 t-cellereceptorer
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US20170151281A1 (en) * 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
AU2016255535A1 (en) 2015-04-30 2017-11-16 University Of Southern California Secretory TNT CAR cell immunotherapy
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
US11116795B2 (en) 2015-07-10 2021-09-14 The Trustees Of The University Of Pennsylvania Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
CN108025024B (zh) 2015-07-28 2022-11-29 宾夕法尼亚大学董事会 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途
AU2015376656B2 (en) 2015-08-07 2018-01-04 Shenzhen In Vivo Biomedicine Technology Limited Company Chimeric antigen receptor containing a Toll-like receptor intracellular domain
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
KR20180054600A (ko) 2015-10-13 2018-05-24 브라이엄 영 유니버시티 면역치료에서의 대식세포 키메라 항원 수용체(moto-car)
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
US11034739B2 (en) 2015-11-13 2021-06-15 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
US20180186855A1 (en) 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
US10875919B2 (en) * 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
CA3025516A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
CN107522786A (zh) 2016-06-20 2017-12-29 深圳市体内生物医药科技有限公司 一种分子、表达其的细胞及其制备方法和用途
WO2018031419A1 (en) * 2016-08-12 2018-02-15 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
RU2019112860A (ru) 2016-09-27 2020-10-30 Серо Терапьютикс, Инк. Молекулы химерных интернализационных рецепторов
JP7303749B2 (ja) 2017-01-13 2023-07-05 セルダラ メディカル、エルエルシー Ｔｉｍ－１を標的とするキメラ抗原受容体
WO2018212770A1 (en) 2017-05-17 2018-11-22 Thunder Biotech Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
WO2018220224A1 (en) 2017-06-02 2018-12-06 Medirista Biotechnologies Ab Lipid-related antigens and antibodies directed against them
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
GB201717974D0 (en) 2017-10-31 2017-12-13 Univ Court Of The Univ Of Aberdeen Modified receptors
EP3707248A4 (en) 2017-11-10 2021-08-18 Chineo Medical Technology Co., Ltd. MODIFIED IMMUNE CELLS AND THEIR USES
JP7387613B2 (ja) 2018-02-09 2023-11-28 ザ トラスティーズ オブ ダートマス カレッジ 神経変性疾患及び障害の治療のためのキメラ抗原受容体
US20210015865A1 (en) 2018-03-28 2021-01-21 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
MX2020010235A (es) 2018-03-28 2020-10-28 Cero Therapeutics Inc Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
EP3774865A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
TWI809130B (zh) 2018-06-22 2023-07-21 美商凱特製藥公司 嵌合跨膜蛋白及其用途
WO2020114518A1 (zh) 2018-12-07 2020-06-11 科济生物医药（上海）有限公司 肿瘤联合免疫治疗
KR20220045930A (ko) 2019-04-30 2022-04-13 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 이의 사용 방법
JP2022539587A (ja) 2019-07-03 2022-09-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｂ細胞悪性腫瘍の処置のために細胞表面マーカーｃｄ７２を標的とする免疫療法
WO2021067875A1 (en) 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
US20210253696A1 (en) 2020-01-21 2021-08-19 Cero Therapeutics, Inc. Bivalent chimeric engulfment receptors and uses thereof
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
US20250127896A1 (en) 2021-07-28 2025-04-24 Cero Therapeutics Holdings, Inc. Chimeric tim4 receptors and uses thereof

Also Published As

Publication number Publication date
WO2019067328A1 (en) 2019-04-04
JP2025102799A (ja) 2025-07-08
US20240174766A1 (en) 2024-05-30
IL272803A (en) 2020-04-30
EP3688032B1 (en) 2025-11-05
EP4714966A2 (en) 2026-03-25
FI3688032T3 (fi) 2025-12-09
JP7286658B2 (ja) 2023-06-05
EP3688032A1 (en) 2020-08-05
CN111386284B (zh) 2024-08-30
US20200308305A1 (en) 2020-10-01
RU2020114641A (ru) 2021-10-27
ES3058444T3 (es) 2026-03-10
KR20200100598A (ko) 2020-08-26
CA3073421A1 (en) 2019-04-04
JP2020534871A (ja) 2020-12-03
US11708423B2 (en) 2023-07-25
AU2018341244A1 (en) 2020-03-05
JP2023120201A (ja) 2023-08-29
RU2020114641A3 (da) 2022-03-03
MX2020007266A (es) 2020-09-07
CN111386284A (zh) 2020-07-07

Similar Documents

Publication Publication Date Title
IL272803A (en) Chimeric Ingestion Receptor Molecules and Methods of Use
DK3601367T3 (da) Kimære molekyler og anvendelse deraf
DK3436030T3 (da) Kimæriske receptorer og fremgangsmåder til anvendelse deraf
IL271025A (en) Multibiotic agents and methods of using the same
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3596053T3 (da) Farnesoid-x-receptoragonister og anvendelser deraf
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3551209T3 (da) Insulin-fc-fusioner og fremgangsmåder til anvendelse
DK4105223T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3350165T3 (da) Farnesoid-X-receptoragonister og anvendelser deraf
DK3828194T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3264955T3 (da) Blandeanordning og fremgangsmåde
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3126394T3 (da) Anti-OX40-antistoffer og fremgangsmåder til anvendelse
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3169703T4 (da) Kimær antigenreceptor og anvendelse deraf